Double-blind trial of promegestone (R 5020) and lynestrenol in the treatment of benign breast disease.

Abstract

One hundred thirty-two women between the ages of 19 and 50, with various forms of benign breast diseases received 1 mg promegestone, or 0.5 mg promegestone, or 10 mg lynestrenol daily (double-blind), for 15 days per cycle, during three cycles. The groups were identical before treatment, with the exception of a longer history of mastodynia and mastopathies… (More)

Topics

  • Presentations referencing similar topics